Mavacamten FDA approval date

The FDA approved Mavacamten (BMS-986327) on 28 Apr 2022.

FDA approval date
28 Apr 2022

Drug identity checked against registry records

Also recorded as BMS-986327; MYK-461

Included trials

TrialSponsorPhaseStatusPrimary completion
A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCMNCT05174416LianBio LLCPhase 3Completed2023-03-06Actual

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2022-04-28DayMavacamtenFDA original application approvalFDA approval decisionNot specifiedOpen original source
Read source excerpt

{"application_number": "NDA214998", "applicant_as_listed_by_fda": "BRISTOL", "brand_names": ["CAMZYOS"], "active_ingredients": ["MAVACAMTEN"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20220428", "matched_on": "drug name equals FDA sole active ingredient"}

First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026